London, March 2022: RX Japan www.rxglobal.com/jp has launched Femtech Tokyo, a brand new event which aims to help breakdown taboos around women’s health, and tap into a rapidly expanding growth market.

Femtech Tokyo takes place over three days from 20-22 October at Tokyo Big Sight. The first two days will be dedicated to business, enabling developers of female technology products and services to meet with retailers, wholesalers, importers, manufacturers and investors. The final day of the show will be open to the public, enabling exhibitors to raise brand awareness and sell their health and wellness solutions direct to consumers. Over 200 exhibitors and 20,000 visitors are expected to attend.

‘Femtech’ refers to technologies specifically focused on women’s health, covering a broad range of areas from hormonal disorders and period pain to fertility, birth control, sexual wellness and the menopause. The term is attributed to Ida Tin, the Danish-born founder of Clue, a period and ovulation tracking app created in Germany in 2013.

Historically, medicine and its technologies have been dominated by male experts, with industry attention being largely centred on men’s bodies and male experiences of illness. Awareness of this inequality, or the "gender health gap" has grown significantly over the past five years, driven by social justice and equality advocates, and accelerated by Covid-19.

According to U.S. research company Frost & Sullivan, the global market for femtech is expected to be worth over USD40 billion annually by 2025.

The idea for Femtech Tokyo came to Atomu Shimoda, Event Director, as a result of his research into the market. “On the one hand I saw the huge potential for this market, but on the other I learned that we are lagging behind in Japan due to long-held taboos around women’s health, which makes it difficult for women to talk openly about what are perceived to be ‘delicate’ issues.”

“I saw an opportunity to launch an event that could help to disrupt these outdated ideas, and make a significant impact on society by raising awareness about women’s health, driving femtech innovation, and empowering women to take control of their wellness,” Atomu continued. “Once the proposal got the go-ahead, we decided to launch straight away to support what we expect will be a huge growth market.”

ENDS

For further information, please contact Sarah Kitley-Spencer: 
Email: Sarah.Kitley-Spencer@rxglobal.com  Telephone: +44 (0)7813 777947

About RX (Reed Exhibitions)

RX is in the business of building businesses for individuals, communities and organisations. We elevate the power of face to face events by combining data and digital products to help customers learn about markets, source products and complete transactions at over 400 events in 22 countries across 43 industry sectors. RX is passionate about making a positive impact on society and is fully committed to creating an inclusive work environment for all our people. RX is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.rxglobal.com

About RELX
RELX is a global provider of information-based analytics and decision tools for professional
and business customers. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs over 33,000 people, of whom almost half are in North America. The shares of RELX PLC, the parent company, are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.  The market capitalisation is approximately £44.8bn, €53.8bn, $59.1bn.*

*Note: Current market capitalisation can be found at http://www.relx.com/investors